News
-
Genelux Corporation Announces Early Results Of A Phase I/II Clinical Trial Of Virotherapeutic GL-ONC1 In Advanced Peritoneal Cavity Cancers
11/1/2012
Genelux Corporation, a clinical-stage biopharmaceutical company developing vaccinia virus based oncolytic cancer therapies and companion diagnostics, announced early results of the first patient cohort treated in a Phase I/II clinical trial with GL-ONC1, its leading virotherapeutic product candidate, in patients with advanced peritoneal cavity cancers. As presented at the 8thWorld Congress on Peritoneal Surface Malignancies in Berlin, Germany, GL-ONC1 was found to be clinically well tolerated when applied directly into the peritoneal cavity.
-
Isis Pharmaceuticals Initiates Phase 1b/2a Study Of ISIS-SMNRx In Patients With Spinal Muscular Atrophy
11/1/2012
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 1b/2a study evaluating ISIS-SMNRx in children with spinal muscular atrophy (SMA).
-
Novartis To Start Construction Of New Biotechnology Facility In Singapore With An Investment Of Over USD 500 Million
10/31/2012
Novartis announced recently the construction of a new state-of-the-art biotechnology production site in Singapore with an investment valued at over USD 500 million. The new facility will focus on drug substance manufacturing based on cell culture technology.
-
ViaCyte Receives $10.1M Strategic Partnership Award From CIRM To Continue Development Of Diabetes Therapy
10/26/2012
ViaCyte, Inc., a leading regenerative medicine company developing a transformative cell therapy for treatment of diabetes, announced today that it has received a $10.1 million Strategic Partnership Award from the California Institute for Regenerative Medicine (CIRM).
-
Phase IIa Laquinimod Trial Results Show Positive Data For Potential Use In Active Crohn's Disease
10/22/2012
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced the presentation of Phase IIa clinical data for investigational laquinimod in moderate to severe Crohn's disease (CD).
-
Aeras Signs Agreement With GSK To Jointly Advance TB Vaccine
10/10/2012
Aeras announces that it has signed an agreement with GlaxoSmithKline Vaccines, S.A. (GSK) to jointly advance the clinical development of an investigational tuberculosis (TB) vaccine containing GSK’s proprietary M72 antigen and AS01E adjuvant.
-
Genetic Immunity Receives GMP Certification For In-House Manufacturing Facility
10/8/2012
Genetic Immunity (OTCBB: PWRV) is pleased to announce the GMP approval of its manufacturing facility. The development of the GMP manufacturing process and the facility was financed from a $4 million grant received from the Hungarian Office for Innovation and Technology.
-
Advanced BioScience Laboratories Awards Avid Bioservices HIV Vaccine Development And Manufacturing Contract
9/27/2012
Avid Bioservices, a subsidiary of Peregrine Pharmaceuticals, Inc., today announced that it has been chosen by Advanced BioScience Laboratories, Inc. (ABL) to provide development and large-scale manufacturing services to support cGMP production of an HIV envelope protein, as a component of a preventive vaccine against HIV infection.
-
MYOS Begins Groundbreaking Clinical Study On Muscle Health; Research Designed To Validate The Strengths Of MYO-T12
9/20/2012
MYOS Corporation (OTCBB: MYOS), a company focused on the discovery, development and commercialization of muscle health and performance therapeutic products, today announced that it has initiated a broad human clinical research study designed to confirm the unique myostatin modulating activities of its first product, MYO-T12™.
-
ImaginAb And MacroGenics Collaborate To Develop In Vivo Imaging Agents For Autoimmune Diseases, Cancer
9/5/2012
ImaginAb, Inc. a developer of in vivo molecular imaging agents based on its proprietary antibody fragment platform, recently announced that it has entered into a collaboration and commercialization agreement with MacroGenics, Inc.